GE HealthCare Beats on Q3 Growth, Lifts Full-Year Guidance
GEHC sits 22% above its 52-week low of $58.75.
Summary
GE HealthCare delivered Q3 revenue of $5.5 billion, up 7.2% with organic growth of 6.2%, and grew adjusted EPS to $1.34 from $1.07 a year ago. GAAP EPS was $1.36, and cash flow from operating activities was $907 million with free cash flow of $793 million, both including a $55 million tariff refund. Adjusted EBIT margin expanded 180 bps to 16.6% on volume, price and cost productivity plus a favorable tariff swing. All three segments grew, and Patient Care Solutions — a drag in recent quarters — posted 8.5% revenue growth with segment EBIT up 148.8%. Management raised full-year 2026 guidance: organic growth to ~4.0% from 3.0-4.0%, and adjusted EPS to $4.95-$5.05 from $4.80-$5.00, and now sees 2025 free cash flow of $1.6 billion or more. Orders grew 4.0% organically with a 1.03 book-to-bill and $23.7 billion backlog, a step down from the 11% order growth reported in Q2. The company also announced PCS CEO Jeannette Bankes is leaving for a CEO role elsewhere, with Neal Sandy taking over November 16, and raised the quarterly dividend 14% to $0.04. The earnings call is today at 8:30 am ET.
Updates
· SEC 8-K — GE HealthCare's 8-K confirms PCS CEO Jeannette Bankes resigns effective November 15, 2026, with Neal Sandy becoming PCS President and CEO on November 16, 2026.
At the time of this announcement, GEHC was trading at $71.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.1B. The 52-week trading range was $58.75 to $89.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.